Resistance to anti-cancer drugs is a phenomena that can have massive impact on cancer care, and needs to be closely monitored by clinicians involved in cancer care. Identifying both when the loss of efficacy in cancer drugs begins, and also the mechanism by which this resistance develops is of vital importance to clinicians and researchers tasked with identifying the issue, theorizing solutions, and implementing new treatments in the wake of resistance. The ultimate goal in these instances must be that of treating the cancer and preventing further resistance developing further down the line. By identifying these often unpredictable mechanisms of resistance, new refined drug molecules or drug delivery methods can be developed to avoid cancer drug resistance and ensure patient care is optimum.
Resistance can come about from a number of different ways, which makes the research into these mechanisms vital. By identifying incidences of developing resistance sooner, and being able to categorize them can enable clinicians to amend treatment pathways sooner, improving patient outcomes by not allowing tumor regeneration during the period of minimal anti-cancer drug efficacy. To researchers, the emerging research featured in this collection concerning novel resistance mechanisms can focus on finding methods of bypassing resistance, through altering drug molecules, using combination treatments, or employing newer methods including nanoparticle systems for delivery, or the use of exosomes.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Identifying methods by which response to anticancer drug molecules diminishes
- Identifying new ways to bypass resistance
- Novel delivery methods with decrease risk of drug-resistance
- Drug combination therapies which preserve and prolong efficacy
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Resistance to anti-cancer drugs is a phenomena that can have massive impact on cancer care, and needs to be closely monitored by clinicians involved in cancer care. Identifying both when the loss of efficacy in cancer drugs begins, and also the mechanism by which this resistance develops is of vital importance to clinicians and researchers tasked with identifying the issue, theorizing solutions, and implementing new treatments in the wake of resistance. The ultimate goal in these instances must be that of treating the cancer and preventing further resistance developing further down the line. By identifying these often unpredictable mechanisms of resistance, new refined drug molecules or drug delivery methods can be developed to avoid cancer drug resistance and ensure patient care is optimum.
Resistance can come about from a number of different ways, which makes the research into these mechanisms vital. By identifying incidences of developing resistance sooner, and being able to categorize them can enable clinicians to amend treatment pathways sooner, improving patient outcomes by not allowing tumor regeneration during the period of minimal anti-cancer drug efficacy. To researchers, the emerging research featured in this collection concerning novel resistance mechanisms can focus on finding methods of bypassing resistance, through altering drug molecules, using combination treatments, or employing newer methods including nanoparticle systems for delivery, or the use of exosomes.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Identifying methods by which response to anticancer drug molecules diminishes
- Identifying new ways to bypass resistance
- Novel delivery methods with decrease risk of drug-resistance
- Drug combination therapies which preserve and prolong efficacy
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
